Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

L. Kappos; D. Li; P.A. Calabresi; P. O'Connor; A. Bar-Or; F. Barkhof; M. Yin; D. Leppert; R. Glanzman; J. Tinbergen; S.L. Hauser

doi:10.1016/S0140-6736(11)61649-8

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

L. Kappos, D. Li, P.A. Calabresi, P. O'Connor, A. Bar-Or, F. Barkhof, M. Yin, D. Leppert, R. Glanzman, J. Tinbergen, S.L. Hauser

Radiology and nuclear medicine

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1779-1787
Journal	Lancet
Volume	378
Issue number	9805
DOIs	https://doi.org/10.1016/S0140-6736(11)61649-8
Publication status	Published - 2011

Access to Document

10.1016/S0140-6736(11)61649-8

Cite this

@article{c0a3f37c3bb54994b97ff8a4c9c4097a,

title = "Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial",

author = "L. Kappos and D. Li and P.A. Calabresi and P. O'Connor and A. Bar-Or and F. Barkhof and M. Yin and D. Leppert and R. Glanzman and J. Tinbergen and S.L. Hauser",

year = "2011",

doi = "10.1016/S0140-6736(11)61649-8",

language = "Undefined/Unknown",

volume = "378",

pages = "1779--1787",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "9805",

}

TY - JOUR

T1 - Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

AU - Kappos, L.

AU - Li, D.

AU - Calabresi, P.A.

AU - O'Connor, P.

AU - Bar-Or, A.

AU - Barkhof, F.

AU - Yin, M.

AU - Leppert, D.

AU - Glanzman, R.

AU - Tinbergen, J.

AU - Hauser, S.L.

PY - 2011

Y1 - 2011

U2 - 10.1016/S0140-6736(11)61649-8

DO - 10.1016/S0140-6736(11)61649-8

M3 - Article

VL - 378

SP - 1779

EP - 1787

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9805

ER -